Showing results (2081-2090 of 2,199) with videos related to
Sort By:
Pageof 220
Developments in Biological Standardization|January 1, 1993
Assessment of the viral RNA sequence heterogeneity for control of OPV neurovirulenceK Chumakov, L Norwood, M Parker, et al.Developments in Biological Standardization|January 1, 1996
Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccinesE Rooijakkers, J Groen, J Uittenbogarrd, et al.Developments in Biological Standardization|January 1, 1996
Detection of extraneous agents in vaccines using the polymerase chain reaction of Newcastle disease virus in poultry biologicalsL Bruckner, N Stäuber, K Brechtbühl, et al.Developments in Biological Standardization|January 1, 1996
Validation of the toxin-binding inhibition (ToBI) test for the estimation of the potency of the tetanus toxoïd component in vaccinesJ van der Gun, A Akkermans, C Hendriksen, et al.Developments in Biological Standardization|January 1, 1996
Use of in vitro Vero cell assay and ELISA in the United States potency test of vaccines containing adsorbed diphtheria and tetanus toxoidsR K Gupta, G R SiberDevelopments in Biological Standardization|January 1, 1996
Comparison of in vivo and in vitro methods for determining unitage of diphtheria antitoxin in adsorbed diphtheria-tetanus (DT) and diphtheria-tetanus-pertussis (DTP) vaccinesY P Shinde, S S JadhavDevelopments in Biological Standardization|January 1, 1996
Pertussis serological potency test as an alternatively to the intracerebral mouse protection testA van der Ark, I van Straaten-van de Kappelle, C Hendriksen, et al.Developments in Biological Standardization|January 1, 1996
WHO activities towards the three Rs in the development and control of biological productsJ Milstien, V Grachev, A Padilla, et al.Developments in Biological Standardization|January 1, 1996
Evaluation of new approaches to poliovirus vaccine neurovirulence testsD J WoodDevelopments in Biological Standardization|January 1, 1996
The safety of biopharmaceutical products--a personal viewpointN B FinterPageof 220